Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review

Journal of Controlled Release

Volumn 214, Issue , 2015, Pages 40-61

  Azevedo, Rita ^a,b   Ferreira, José Alexandre ^a,c   Peixoto, Andreia ^a   Neves, Manuel ^a,b   Sousa, Nuno ^a   Lima, Aurea ^a,d   Santos, Lucio Lara ^a,e  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^e UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Antibody based therapeutics; Bladder cancer; Immunotherapy; Personalized medicine; Targeted therapy

Indexed keywords

ANTIBODIES; CHEMOTHERAPY; TUMORS;

BIOMOLECULAR PATHWAY; BLADDER CANCERS; FUTURE PERSPECTIVES; IMMUNOTHERAPY; PERSONALIZED MEDICINES; SYSTEMATIC REVIEW; TARGETED THERAPY; THERAPEUTIC STRATEGY;

DISEASES;

ANGIOPOIETIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR; PROTEIN INHIBITOR; TIE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR ANTIGEN; VASCULOTROPIN RECEPTOR; ANTIBODY; ANTINEOPLASTIC AGENT;

ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; ANIMAL; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES; URINARY BLADDER NEOPLASMS;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; URINARY BLADDER NEOPLASMS;

EID: 84938149573     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.07.002     Document Type: Review

References (188)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 2014 2014 9 29 10.3322/caac.21208
2. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur. J. Cancer 46 2010 2010 765 781 10.1016/j.ejca.2009.12.014
3. M.E. Nielsen, A.B. Smith, A.M. Meyer, T.M. Kuo, S. Tyree, W.Y. Kim, M.I. Milowsky, R.S. Pruthi, and R.C. Millikan Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006 Cancer 120 2014 2014 86 95 10.1002/cncr.28397
4. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Version 1 http://www.nccn.org/professionals/physician-gls/f-guidelines.asp 2008 (Accessed at February 2015)
5. M. Babjuk, M. Burger, R. Zigeuner, S.F. Shariat, B.W. van Rhijn, E. Comperat, R.J. Sylvester, E. Kaasinen, A. Bohle, J. Palou Redorta, M. Roupret, and U. European Association of, EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013 Eur. Urol. 64 2013 2013 639 653 10.1016/j.eururo.2013.06.003
6. A. Stenzl, N.C. Cowan, M. De Santis, M.A. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes, and U. European Association of treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur. Urol. 59 2011 2011 1009 1018 10.1016/j.eururo.2011.03.023
7. H.B. Grossman, R.B. Natale, C.M. Tangen, V.O. Speights, N.J. Vogelzang, D.L. Trump, R.W. deVere White, M.F. Sarosdy, D.P. Wood Jr., D. Raghavan, and E.D. Crawford Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N. Engl. J. Med. 349 2003 2003 859 866 10.1056/NEJMoa022148
8. H. von der Maase, L. Sengelov, J.T. Roberts, S. Ricci, L. Dogliotti, T. Oliver, M.J. Moore, A. Zimmermann, and M. Arning Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J. Clin. Oncol. 23 2005 2005 4602 4608 10.1200/JCO.2005.07.757
9. G. Cheung, A. Sahai, M. Billia, P. Dasgupta, and M.S. Khan Recent advances in the diagnosis and treatment of bladder cancer BMC Med. 11 2013 2013 13 10.1186/1741-7015-11-13
10. D.A. Lipschitz, S. Goldstein, R. Reis, M.E. Weksler, R. Bressler, and B.A. Neilan Cancer in the elderly: basic science and clinical aspects Ann. Intern. Med. 102 1985 1985 218 228
11. A. Necchi, P. Giannatempo, L. Mariani, E. Fare, D. Raggi, M. Pennati, N. Zaffaroni, F. Crippa, A. Marchiano, N. Nicolai, M. Maffezzini, E. Togliardi, M.G. Daidone, A.M. Gianni, R. Salvioni, and F. De Braud PF-03446962, a fully-human monoclonal antibody against transforming growth-factor beta (TGFbeta) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial Investig. New Drugs 32 2014 555 560 10.1007/s10637-014-0074-9
12. T. Powles, J.P. Eder, G.D. Fine, F.S. Braiteh, Y. Loriot, C. Cruz, J. Bellmunt, H.A. Burris, D.P. Petrylak, S.L. Teng, X. Shen, Z. Boyd, P.S. Hegde, D.S. Chen, and N.J. Vogelzang MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558 562 10.1038/nature13904
13. F. Massari, C. Ciccarese, M. Santoni, M. Brunelli, A. Conti, A. Modena, R. Montironi, D. Santini, L. Cheng, G. Martignoni, S. Cascinu, and G. Tortora The route to personalized medicine in bladder cancer: where do we stand? Target. Oncol. 2015 2015 10.1007/s11523-015-0357-x
14. B.A. Carneiro, J.J. Meeks, T.M. Kuzel, M. Scaranti, S.A. Abdulkadir, and F.J. Giles Emerging therapeutic targets in bladder cancer Cancer Treat. Rev. 41 2015 170 178 10.1016/j.ctrv.2014.11.003
15. J.J. Meeks, J. Bellmunt, B.H. Bochner, N.W. Clarke, S. Daneshmand, M.D. Galsky, N.M. Hahn, S.P. Lerner, M. Mason, T. Powles, C.N. Sternberg, and G. Sonpavde A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer Eur. Urol. 62 2012 2012 523 533 10.1016/j.eururo.2012.05.048
16. G. Ploussard, S. Daneshmand, J.A. Efstathiou, H.W. Herr, N.D. James, C.M. Rodel, S.F. Shariat, W.U. Shipley, C.N. Sternberg, G.N. Thalmann, and W. Kassouf Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review Eur. Urol. 66 2014 2014 120 137 10.1016/j.eururo.2014.02.038
17. R.O. Dillman Cancer immunotherapy Cancer Biother. Radiopharm. 26 2011 2011 1 64 10.1089/cbr.2010.0902
18. A.M. Scott, J.D. Wolchok, and L.J. Old Antibody therapy of cancer Nat. Rev. Cancer 12 2012 2012 278 287 10.1038/nrc3236
19. N. Cancer Genome Atlas Research Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507 2014 2014 315 322 10.1038/nature12965
20. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, J.P. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, and D. Moher The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med. 6 2009 e1000100 10.1371/journal.pmed.1000100
21. P. Traxler Tyrosine kinases as targets in cancer therapy - successes and failures Expert Opin. Ther. Targets 7 2003 2003 215 234 10.1517/14728222.7.2.215
22. J. Qing, X. Du, Y. Chen, P. Chan, H. Li, P. Wu, S. Marsters, S. Stawicki, J. Tien, K. Totpal, S. Ross, S. Stinson, D. Dornan, D. French, Q.R. Wang, J.P. Stephan, Y. Wu, C. Wiesmann, and A. Ashkenazi Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice J. Clin. Invest. 119 2009 2009 1216 1229 10.1172/JCI38017
23. S. Grant, L. Qiao, and P. Dent Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival Front. Biosci. 7 2002 2002 d376 d389
24. M. Bartoli, X. Gu, N.T. Tsai, R.C. Venema, S.E. Brooks, M.B. Marrero, and R.B. Caldwell Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells J. Biol. Chem. 275 2000 2000 33189 33192 10.1074/jbc.C000318200
25. P. ten Dijke, and C.S. Hill New insights into TGF-beta-Smad signalling Trends Biochem. Sci. 29 2004 2004 265 273 10.1016/j.tibs.2004.03.008
26. M. Jost, C. Kari, and U. Rodeck The EGF receptor - an essential regulator of multiple epidermal functions Eur. J. Dermatol. 10 2000 2000 505 510
27. K. Mellon, C. Wright, P. Kelly, C.H. Horne, and D.E. Neal Long-term outcome related to epidermal growth factor receptor status in bladder cancer J. Urol. 153 1995 1995 919 925
28. E.M. Messing Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma Cancer Res. 50 1990 1990 2530 2537
29. W. Kassouf, P.C. Black, T. Tuziak, J. Bondaruk, S. Lee, G.A. Brown, L. Adam, C. Wei, K. Baggerly, M. Bar-Eli, D. McConkey, B. Czerniak, and C.P. Dinney Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer J. Urol. 179 2008 2008 353 358 10.1016/j.juro.2007.08.087
30. P. Bue, K. Wester, A. Sjostrom, A. Holmberg, S. Nilsson, J. Carlsson, J.E. Westlin, C. Busch, and P.U. Malmstrom Expression of epidermal growth factor receptor in urinary bladder cancer metastases Int. J. Cancer 76 1998 1998 189 193
31. J.L. Dominguez-Escrig, J.D. Kelly, D.E. Neal, S.M. King, and B.R. Davies Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer Clin. Cancer Res. 10 2004 2004 4874 4884 10.1158/1078-0432.CCR-04-0034
32. M. Shrader, M.S. Pino, L. Lashinger, M. Bar-Eli, L. Adam, C.P. Dinney, and D.J. McConkey Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression Cancer Res. 67 2007 2007 1430 1435 10.1158/0008-5472.CAN-06-1224
33. R.A. Mason, E.V. Morlock, M.R. Karagas, K.T. Kelsey, C.J. Marsit, A.R. Schned, and A.S. Andrew EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis Carcinogenesis 30 2009 2009 1155 1160 10.1093/carcin/bgp077
34. K.N. Blehm, P.E. Spiess, J.E. Bondaruk, M.E. Dujka, G.J. Villares, Y.J. Zhao, O. Bogler, K.D. Aldape, H.B. Grossman, L. Adam, D.J. McConkey, B.A. Czerniak, C.P. Dinney, and M. Bar-Eli Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy Clin. Cancer Res. 12 2006 2006 4671 4677 10.1158/1078-0432.CCR-06-0407
35. G. Toffoli, E. De Mattia, E. Cecchin, P. Biason, S. Masier, and G. Corona Pharmacology of epidermal growth factor inhibitors Int. J. Biol. Markers 22 2007 2007 S24 S39
36. L.M. Weiner Fully human therapeutic monoclonal antibodies J. Immunother. 29 2006 2006 1 9
37. Food and Drug Administration (FDA) Vectibix® (panitumumab) http://www.cancer.gov/cancertopics/druginfo/fda-panitumumab 2008 (Accessed at March 2015)
38. European Medicines Agency (EMA) Vectibix® (panitumumab) http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/human/000741/WC500047704.pdf 2007 (Accessed at May 2015)
39. X.D. Yang, X.C. Jia, J.R. Corvalan, P. Wang, and C.G. Davis Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy Crit. Rev. Oncol. Hematol. 38 2001 2001 17 23
40. K.A. Foon, X.D. Yang, L.M. Weiner, A.S. Belldegrun, R.A. Figlin, J. Crawford, E.K. Rowinsky, J.P. Dutcher, N.J. Vogelzang, J. Gollub, J.A. Thompson, G. Schwartz, R.M. Bukowski, L.K. Roskos, and G.M. Schwab Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody Int. J. Radiat. Oncol. Biol. Phys. 58 2004 2004 984 990 10.1016/j.ijrobp.2003.09.098
41. J.J. Stephenson, C. Gregory, H. Burris, T. Larson, U. Verma, A. Cohn, J. Crawford, R.B. Cohen, J. Martin, P. Lum, X. Yang, and R.G. Amado An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors Clin. Colorectal Cancer 8 2009 2009 29 37 10.3816/CCC.2009.n.005
42. M.K. Wilson, K. Karakasis, and A.M. Oza Outcomes and endpoints in trials of cancer treatment: the past, present, and future Lancet Oncol. 16 2015 2015 e32 e42 10.1016/S1470-2045(14)70375-4
43. U.S. department of health and human services Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf 2010 (Accessed at February 2015)
44. R.S. Herbst, and D.M. Shin Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy Cancer 94 2002 2002 1593 1611
45. Food and Drug Administration (FDA) Erbitux® (cetuximab) http://www.cancer.gov/cancertopics/druginfo/fda-cetuximab 2007 (Accessed at March 2015)
46. European Medicines Agency (EMA) Erbitux® (cetuximab) http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/human/000558/WC500029111.pdf 2004 (Accessed at May 2015)
47. P. Perrotte, T. Matsumoto, K. Inoue, H. Kuniyasu, B.Y. Eve, D.J. Hicklin, R. Radinsky, and C.P. Dinney Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice Clin. Cancer Res. 5 1999 1999 257 265
48. K. Inoue, J.W. Slaton, P. Perrotte, D.W. Davis, C.J. Bruns, D.J. Hicklin, D.J. McConkey, P. Sweeney, R. Radinsky, and C.P. Dinney Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma Clin. Cancer Res. 6 2000 2000 4874 4884
49. Y.N. Wong, S. Litwin, D. Vaughn, S. Cohen, E.R. Plimack, J. Lee, W. Song, M. Dabrow, M. Brody, H. Tuttle, and G. Hudes Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma J. Clin. Oncol. 30 2012 2012 3545 3551 10.1200/JCO.2012.41.9572
50. M.P. Morelli, T. Cascone, T. Troiani, F. De Vita, M. Orditura, G. Laus, S.G. Eckhardt, S. Pepe, G. Tortora, and F. Ciardiello Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors Ann. Oncol. 16 Suppl. 4 (2005) 2005 iv61 iv68 10.1093/annonc/mdi910
51. M. Hussain, S. Daignault, N. Agarwal, P.D. Grivas, A.O. Siefker-Radtke, I. Puzanov, G.R. MacVicar, E.G. Levine, S. Srinivas, P. Twardowski, M.A. Eisenberger, D.I. Quinn, U.N. Vaishampayan, E.Y. Yu, S. Dawsey, K.C. Day, M.L. Day, M. Al-Hawary, and D.C. Smith A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma Cancer 120 2014 2014 2684 2693 10.1002/cncr.28767
52. D.L. Wheeler, S. Huang, T.J. Kruser, M.M. Nechrebecki, E.A. Armstrong, S. Benavente, V. Gondi, K.T. Hsu, and P.M. Harari Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members Oncogene 27 2008 2008 3944 3956 10.1038/onc.2008.19
53. K. Wester, A. Sjostrom, M. de la Torre, J. Carlsson, and P.U. Malmstrom HER-2 - a possible target for therapy of metastatic urinary bladder carcinoma Acta Oncol. 41 2002 2002 282 288
54. J. Zhao, W. Xu, Z. Zhang, R. Song, S. Zeng, Y. Sun, and C. Xu Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis Int. Urol. Nephrol. 47 2015 2015 87 94 10.1007/s11255-014-0866-z
55. M. Yan, M. Schwaederle, D. Arguello, S.Z. Millis, Z. Gatalica, and R. Kurzrock HER2 expression status in diverse cancers: review of results from 37,992 patients Cancer Metastasis Rev. 34 2015 2015 157 164 10.1007/s10555-015-9552-6
56. S. Gunia, S. Koch, O.W. Hakenberg, M. May, C. Kakies, and A. Erbersdobler Different HER2 protein expression profiles aid in the histologic differential diagnosis between urothelial carcinoma in situ (CIS) and non-CIS conditions (dysplasia and reactive atypia) of the urinary bladder mucosa Am. J. Clin. Pathol. 136 2011 2011 881 888 10.1309/AJCPKUZ69LXZGFEA
57. A. Fleischmann, D. Rotzer, R. Seiler, U.E. Studer, and G.N. Thalmann Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours Eur. Urol. 60 2011 2011 350 357 10.1016/j.eururo.2011.05.035
58. J.S. Ross, K. Wang, L.M. Gay, R.N. Al-Rohil, T. Nazeer, C.E. Sheehan, T.A. Jennings, G.A. Otto, A. Donahue, J. He, G. Palmer, S. Ali, M. Nahas, G. Young, E. Labrecque, G. Frampton, R. Erlich, J.A. Curran, K. Brennan, S.R. Downing, R. Yelensky, D. Lipson, M. Hawryluk, V.A. Miller, and P.J. Stephens A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma Clin. Cancer Res. 20 2014 2014 68 75 10.1158/1078-0432.CCR-13-1992
59. N.L. Spector, and K.L. Blackwell Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer J. Clin. Oncol. 27 2009 2009 5838 5847 10.1200/JCO.2009.22.1507
60. Food and Drug Administration (FDA) Herceptin®(trastuzumab) http://www.cancer.gov/cancertopics/druginfo/fda-trastuzumab#Anchor-Breast 2006 (Accessed at March 2015)
61. European Medicines Agency (EMA) Herceptin® (trastuzumab) http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/human/000278/WC500049819.pdf 2000 (Accessed at May 2015)
62. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 2001 783 792 10.1056/NEJM200103153441101
63. N. Robert, B. Leyland-Jones, L. Asmar, R. Belt, D. Ilegbodu, D. Loesch, R. Raju, E. Valentine, R. Sayre, M. Cobleigh, K. Albain, C. McCullough, L. Fuchs, and D. Slamon Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer J. Clin. Oncol. 24 2006 2006 2786 2792 10.1200/JCO.2005.04.1764
64. L. Skagias, E. Politi, A. Karameris, D. Sambaziotis, A. Archondakis, O. Vasou, A. Ntinis, F. Michalopoulou, I. Moreas, H. Koutselini, and E. Patsouris Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years' research J. Buon 14 2009 2009 457 462
65. P. Lipponen, M. Eskelinen, S. Syrjanen, A. Tervahauta, and K. Syrjanen Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder Eur. Urol. 20 1991 1991 238 242
66. M.H. Hussain, G.R. MacVicar, D.P. Petrylak, R.L. Dunn, U. Vaishampayan, P.N. Lara Jr., G.S. Chatta, D.M. Nanus, L.M. Glode, D.L. Trump, H. Chen, D.C. Smith, and I. National Cancer Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial J. Clin. Oncol. 25 2007 2007 2218 2224 10.1200/JCO.2006.08.0994
67. S. Oudard, S. Culine, Y. Vano, F. Goldwasser, C. Theodore, T. Nguyen, E. Voog, E. Banu, A. Vieillefond, F. Priou, G. Deplanque, G. Gravis, A. Ravaud, J.M. Vannetzel, J.P. Machiels, X. Muracciole, M.F. Pichon, J.O. Bay, R. Elaidi, C. Teghom, F. Radvanyi, and P. Beuzeboc Multicentre randomised phase II trial of gemcitabine + platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2 Eur. J. Cancer 51 2015 2015 45 54 10.1016/j.ejca.2014.10.009
68. J.M. Lambert, and R.V.J. Chari Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer J. Med. Chem. 57 2014 2014 6949 6964 10.1021/jm500766w
69. Food and Drug Administration (FDA) Kadcyla®(ado-trastuzumab emtansine) http://www.cancer.gov/cancertopics/druginfo/fda-ado-trastuzumab-emtansine 2013 (Accessed at March 2015)
70. European Medicines Agency (EMA) Kadcyla® (ado-trastuzumab emtansine) http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/human/002389/WC500158596.pdf 2013 (Accessed at May 2015)
71. T. Hayashi, W. Jaeger, I. Moskalev, S. Awrey, N. Li, L. Fazli, W. Yasui, A. Matsubara, and P. Black MP28-14 targeting HER2 with trastuzumab-DM1 (T-DM1) in HER2-overexpressing bladder cancer J. Urol. 191 2014 2014 e301 10.1016/j.juro.2014.02.663
72. T. Hayashi, R. Seiler, H.Z. Oo, W. Jager, I. Moskalev, S. Awrey, T. Dejima, T. Todenhofer, N. Li, L. Fazli, A. Matsubara, and P.C. Black Targeting HER2 with T-DM1, an antibody cytotoxic drug conjugate, is effective in HER2 over-expressing bladder cancer J. Urol. 2015 2015 10.1016/j.juro.2015.05.087
73. J.L. Nordstrom, S. Gorlatov, W. Zhang, Y. Yang, L. Huang, S. Burke, H. Li, V. Ciccarone, T. Zhang, J. Stavenhagen, S. Koenig, S.J. Stewart, P.A. Moore, S. Johnson, and E. Bonvini Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties Breast Cancer Res. 13 2011 2011 R123 10.1186/bcr3069
74. B. Howard, A.G. Giuseppe, I. Seock-Ah, B. Todd Michael, T. Jane, B.N. Jeffrey, L.L. Hua, C. David, A.B. Jan, E.S. Stanford, and B. Yung-Jue Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAb), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein J. Clin. Oncol. 31 2013 2013
75. J. Folkman Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 285 1971 1971 1182 1186 10.1056/NEJM197111182852108
76. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat. Med. 9 2003 2003 669 676 10.1038/nm0603-669
77. G.H. Fong, J. Rossant, M. Gertsenstein, and M.L. Breitman Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium Nature 376 1995 1995 66 70 10.1038/376066a0
78. W. Wu, X. Shu, H. Hovsepyan, R.D. Mosteller, and D. Broek VEGF receptor expression and signaling in human bladder tumors Oncogene 22 2003 2003 3361 3370 10.1038/sj.onc.1206285
79. P.K. Kopparapu, S.A. Boorjian, B.D. Robinson, M. Downes, L.J. Gudas, N.P. Mongan, and J.L. Persson Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer Anticancer Res. 33 2013 2013 2381 2390
80. S. Fauconnet, S. Bernardini, I. Lascombe, G. Boiteux, A. Clairotte, F. Monnien, E. Chabannes, and H. Bittard Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer Oncol. Rep. 21 2009 2009 1495 1504
81. C.C. Yang, K.C. Chu, and W.M. Yeh The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression Urol. Oncol. 22 2004 1 6 10.1016/S1078-1439(03)00015-2
82. G. Xia, S.R. Kumar, D. Hawes, J. Cai, L. Hassanieh, S. Groshen, S. Zhu, R. Masood, D.I. Quinn, D. Broek, J.P. Stein, and P.S. Gill Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer J. Urol. 175 2006 2006 1245 1252 10.1016/S0022-5347(05)00736-6
83. Y. Huang, X. Chen, M.M. Dikov, S.V. Novitskiy, C.A. Mosse, L. Yang, and D.P. Carbone Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF Blood 110 2007 2007 624 631 10.1182/blood-2007-01-065714
84. N.S. Brown, E.H. Streeter, A. Jones, A.L. Harris, and R. Bicknell Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma Br. J. Cancer 92 2005 2005 1696 1701 10.1038/sj.bjc.6602522
85. R. Bhuvaneswari, G.Y. Yuen, S.K. Chee, and M. Olivo Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model Lasers Surg. Med. 43 2011 2011 651 662 10.1002/lsm.21109
86. F.A. Scappaticci Mechanisms and future directions for angiogenesis-based cancer therapies J. Clin. Oncol. 20 2002 2002 3906 3927
87. C.J. Sweeney, K.D. Miller, S.E. Sissons, S. Nozaki, D.K. Heilman, J. Shen, and G.W. Sledge Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors Cancer Res. 61 2001 2001 3369 3372
88. M.F. Press, and H.J. Lenz EGFR, HER2 and VEGF pathways: validated targets for cancer treatment Drugs 67 2007 2007 2045 2075
89. Food and Drug Administration (FDA) Avastin®(bevacizumab) http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab 2014 (Accessed at March 2015)
90. European Medicines Agency (EMA) Avastin® (bevacizumab) http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/human/000582/WC500029260.pdf 2005 (Accessed at May 2015)
91. T. Shih, and C. Lindley Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies Clin. Ther. 28 2006 2006 1779 1802 10.1016/j.clinthera.2006.11.015
92. B. Escudier, A. Pluzanska, P. Koralewski, A. Ravaud, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, B. Melichar, E. Bajetta, V. Gorbunova, J.O. Bay, I. Bodrogi, A. Jagiello-Gruszfeld, N. Moore A.T. investigators Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2007 2103 2111 10.1016/S0140-6736(07)61904-7
93. G. Zhang, S. Huang, and Z. Wang A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme J. Clin. Neurosci. 19 2012 2012 1636 1640 10.1016/j.jocn.2011.12.028
94. N.M. Hahn, W.M. Stadler, R.T. Zon, D. Waterhouse, J. Picus, S. Nattam, C.S. Johnson, S.M. Perkins, M.J. Waddell, C.J. Sweeney, and G. Hoosier Oncology Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75 J. Clin. Oncol. 29 2011 2011 1525 1530 10.1200/JCO.2010.31.6067
95. T. Macarulla, T. Sauri, and J. Tabernero Evaluation of aflibercept in the treatment of metastatic colorectal cancer Expert. Opin. Biol. Ther. 14 2014 2014 1493 1505 10.1517/14712598.2014.947956
96. P. Twardowski, W.M. Stadler, P. Frankel, P.N. Lara, C. Ruel, G. Chatta, E. Heath, D.I. Quinn, and D.R. Gandara Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial Urology 76 2010 2010 923 926 10.1016/j.urology.2010.04.025
97. Food and Drug Administration (FDA) Zaltrap®(Ziv-Aflibercept) http://www.cancer.gov/cancertopics/druginfo/fda-ziv-aflibercept 2012 (Accessed at March 2015)
98. European Medicines Agency (EMA) Zaltrap® (aflibercept) http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/human/002532/WC500139486.pdf 2013 (Accessed at May 2015)
99. J.P. Shaw, R. Basch, and P. Shamamian Hematopoietic stem cells and endothelial cell precursors express Tie-2, CD31 and CD45 Blood Cells Mol. Dis. 32 2004 2004 168 175
100. T.N. Sato, Y. Tozawa, U. Deutsch, K. Wolburg-Buchholz, Y. Fujiwara, M. Gendron-Maguire, T. Gridley, H. Wolburg, W. Risau, and Y. Qin Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation Nature 376 1995 1995 70 74 10.1038/376070a0
101. H. Kobayashi, L.M. DeBusk, Y.O. Babichev, D.J. Dumont, and P.C. Lin Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment Blood 108 2006 2006 1260 1266 10.1182/blood-2005-09-012807
102. S. Davis, T.H. Aldrich, P.F. Jones, A. Acheson, D.L. Compton, V. Jain, T.E. Ryan, J. Bruno, C. Radziejewski, P.C. Maisonpierre, and G.D. Yancopoulos Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning Cell 87 1996 1996 1161 1169
103. H.G. Augustin, G.Y. Koh, G. Thurston, and K. Alitalo Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system Nat. Rev. Mol. Cell Biol. 10 2009 2009 165 177 10.1038/nrm2639
104. S.A. Ahmad, W. Liu, Y.D. Jung, F. Fan, M. Wilson, N. Reinmuth, R.M. Shaheen, C.D. Bucana, and L.M. Ellis The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer Cancer Res. 61 2001 2001 1255 1259
105. A. Coxon, J. Bready, H. Min, S. Kaufman, J. Leal, D. Yu, T.A. Lee, J.R. Sun, J. Estrada, B. Bolon, J. McCabe, L. Wang, K. Rex, S. Caenepeel, P. Hughes, D. Cordover, H. Kim, S.J. Han, M.L. Michaels, E. Hsu, G. Shimamoto, R. Cattley, E. Hurh, L. Nguyen, S.X. Wang, A. Ndifor, I.J. Hayward, B.L. Falcon, D.M. McDonald, L. Li, T. Boone, R. Kendall, R. Radinsky, and J.D. Oliner Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody Mol. Cancer Ther. 9 2010 2010 2641 2651 10.1158/1535-7163.MCT-10-0213
106. J. Oliner, H. Min, J. Leal, D. Yu, S. Rao, E. You, X. Tang, H. Kim, S. Meyer, S.J. Han, N. Hawkins, R. Rosenfeld, E. Davy, K. Graham, F. Jacobsen, S. Stevenson, J. Ho, Q. Chen, T. Hartmann, M. Michaels, M. Kelley, L. Li, K. Sitney, F. Martin, J.R. Sun, N. Zhang, J. Lu, J. Estrada, R. Kumar, A. Coxon, S. Kaufman, J. Pretorius, S. Scully, R. Cattley, M. Payton, S. Coats, L. Nguyen, B. Desilva, A. Ndifor, I. Hayward, R. Radinsky, T. Boone, and R. Kendall Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 Cancer Cell 6 2004 2004 507 516 10.1016/j.ccr.2004.09.030
107. A.C. Mita, C.H. Takimoto, M. Mita, A. Tolcher, K. Sankhala, J. Sarantopoulos, M. Valdivieso, L. Wood, E. Rasmussen, Y.N. Sun, Z.D. Zhong, M.B. Bass, N. Le, and P. LoRusso Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors Clin. Cancer Res. 16 2010 2010 3044 3056 10.1158/1078-0432.CCR-09-3368
108. T. Doi, A. Ohtsu, N. Fuse, T. Yoshino, M. Tahara, K. Shibayama, T. Takubo, and D.M. Weinreich Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors Cancer Chemother. Pharmacol. 71 2013 2013 227 235 10.1007/s00280-012-2000-1
109. L.A. van Meeteren, and P. ten Dijke Regulation of endothelial cell plasticity by TGF-beta Cell Tissue Res. 347 2012 2012 177 186 10.1007/s00441-011-1222-6
110. M. de Caestecker The transforming growth factor-beta superfamily of receptors Cytokine Growth Factor Rev. 15 2004 2004 1 11
111. Y. Shi, and J. Massague Mechanisms of TGF-beta signaling from cell membrane to the nucleus Cell 113 2003 2003 685 700
112. R. Derynck, and Y.E. Zhang Smad-dependent and Smad-independent pathways in TGF-beta family signalling Nature 425 2003 2003 577 584 10.1038/nature02006
113. S. Souchelnytskyi, L. Ronnstrand, C.H. Heldin, and P. ten Dijke Phosphorylation of Smad signaling proteins by receptor serine/threonine kinases Methods Mol. Biol. 124 2001 2001 107 120
114. P. Champelovier, M. El Atifi, F. Mantel, B. Rostaing, A. Simon, F. Berger, and D. Seigneurin In vitro tumoral progression of human bladder carcinoma: role for TGFbeta Eur. Urol. 48 2005 2005 846 851 10.1016/j.eururo.2005.06.005
115. S. Lamouille, C. Mallet, J.J. Feige, and S. Bailly Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis Blood 100 2002 2002 4495 4501 10.1182/blood.V100.13.4495
116. J.H. Kim, S.F. Shariat, I.Y. Kim, A. Menesses-Diaz, H. Tokunaga, T.M. Wheeler, and S.P. Lerner Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder Cancer 92 2001 2001 1475 1483
117. D.D. Hu-Lowe, E. Chen, L. Zhang, K.D. Watson, P. Mancuso, P. Lappin, G. Wickman, J.H. Chen, J. Wang, X. Jiang, K. Amundson, R. Simon, A. Erbersdobler, S. Bergqvist, Z. Feng, T.A. Swanson, B.H. Simmons, J. Lippincott, G.F. Casperson, W.J. Levin, C.G. Stampino, D.R. Shalinsky, K.W. Ferrara, W. Fiedler, and F. Bertolini Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies Cancer Res. 71 2011 2011 1362 1373 10.1158/0008-5472.CAN-10-1451
118. S.I. Cunha, E. Pardali, M. Thorikay, C. Anderberg, L. Hawinkels, M.J. Goumans, J. Seehra, C.H. Heldin, P. ten Dijke, and K. Pietras Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis J. Exp. Med. 207 2010 2010 85 100 10.1084/jem.20091309
119. R.S. Bhatt, and M.B. Atkins Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors? Clin. Cancer Res. 20 2014 2014 2838 2845 10.1158/1078-0432.CCR-13-2788
120. M. Balzar, M.J. Winter, C.J. de Boer, and S.V. Litvinov The biology of the 17-1A antigen (Ep-CAM) J. Mol. Med. (Berl) 77 1999 1999 699 712
121. M. Munz, P.A. Baeuerle, and O. Gires The emerging role of EpCAM in cancer and stem cell signaling Cancer Res. 69 2009 2009 5627 5629 10.1158/0008-5472.CAN-09-0654
122. L. Dolle, N.D. Theise, E. Schmelzer, L. Boulter, O. Gires, and L.A. van Grunsven EpCAM and the biology of hepatic stem/progenitor cells Am. J. Physiol. Gastrointest. Liver Physiol. 308 2015 2015 G233 G250 10.1152/ajpgi.00069.2014
123. P.T. Went, A. Lugli, S. Meier, M. Bundi, M. Mirlacher, G. Sauter, and S. Dirnhofer Frequent EpCam protein expression in human carcinomas Hum. Pathol. 35 2004 2004 122 128
124. S.V. Litvinov, M. Balzar, M.J. Winter, H.A. Bakker, I.H. Briaire-de Bruijn, F. Prins, G.J. Fleuren, and S.O. Warnaar Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins J. Cell Biol. 139 1997 1997 1337 1348
125. A. Brunner, M. Prelog, I. Verdorfer, A. Tzankov, G. Mikuz, and C. Ensinger EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder J. Clin. Pathol. 61 2008 2008 307 310 10.1136/jcp.2007.049460
126. R.T. Bryan, N.J. Shimwell, W. Wei, A.J. Devall, S.J. Pirrie, N.D. James, M.P. Zeegers, K.K. Cheng, A. Martin, and D.G. Ward Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential Br. J. Cancer 110 2014 2014 679 685 10.1038/bjc.2013.744
127. G. Dontu, M. Al-Hajj, W.M. Abdallah, M.F. Clarke, and M.S. Wicha Stem cells in normal breast development and breast cancer Cell Prolif. 36 Suppl 1 2003 2003 59 72
128. C.A. O'Brien, A. Pollett, S. Gallinger, and J.E. Dick A human colon cancer cell capable of initiating tumour growth in immunodeficient mice Nature 445 2007 2007 106 110 10.1038/nature05372
129. C. Di Paolo, J. Willuda, S. Kubetzko, I. Lauffer, D. Tschudi, R. Waibel, A. Pluckthun, R.A. Stahel, and U. Zangemeister-Wittke A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity Clin. Cancer Res. 9 2003 2003 2837 2848
130. I. Pastan, R. Hassan, D.J. Fitzgerald, and R.J. Kreitman Immunotoxin therapy of cancer Nat. Rev. Cancer 6 2006 2006 559 565 10.1038/nrc1891
131. A. Keppler-Hafkemeyer, U. Brinkmann, and I. Pastan Role of caspases in immunotoxin-induced apoptosis of cancer cells Biochemistry 37 1998 1998 16934 16942 10.1021/bi980995m
132. M. Kowalski, J. Entwistle, J. Cizeau, D. Niforos, S. Loewen, W. Chapman, and G.C. MacDonald A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients Drug Des. Devel. Ther. 4 2010 2010 313 320 10.2147/DDDT.S14071
133. A.E. Frankel, R.J. Kreitman, and E.A. Sausville Targeted toxins Clin. Cancer Res. 6 2000 2000 326 334
134. G.C. MacDonald, M. Rasamoelisolo, J. Entwistle, J. Cizeau, D. Bosc, W. Cuthbert, M. Kowalski, M. Spearman, and N. Glover A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck Drug Des. Devel. Ther. 2 2009 2009 105 114
135. J. Brown, M. Rasamoelisolo, M. Spearman, D. Bosc, J. Cizeau, J. Entwistle, and G.C. MacDonald Preclinical assessment of an anti-EpCAM immunotoxin: locoregional delivery provides a safer alternative to systemic administration Cancer Biother. Radiopharm. 24 2009 2009 477 487 10.1089/cbr.2008.0579
136. M. Kowalski, J. Guindon, L. Brazas, C. Moore, J. Entwistle, J. Cizeau, M.A. Jewett, and G.C. MacDonald A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin J. Urol. 188 2012 1712-1718 2012 10.1016/j.juro.2012.07.020
137. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat. Rev. Cancer 12 2012 2012 252 264 10.1038/nrc3239
138. G. Marodon CD4 down modulation on T-cells: an 'immune' checkpoint for HIV Immunol. Lett. 79 2001 2001 165 168
139. S. Mocellin, and D. Nitti CTLA-4 blockade and the renaissance of cancer immunotherapy Biochim. Biophys. Acta 1836 2013 2013 187 196 10.1016/j.bbcan.2013.05.003
140. C.E. Rudd, and H. Schneider Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling Nat. Rev. Immunol. 3 2003 2003 544 556 10.1038/nri1131
141. A. van Elsas, A.A. Hurwitz, and J.P. Allison Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation J. Exp. Med. 190 1999 1999 355 366
142. M. Jure-Kunkel, G. Masters, E. Girit, G. Dito, F. Lee, J.T. Hunt, and R. Humphrey Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models Cancer Immunol. Immunother. 62 2013 2013 1533 1545 10.1007/s00262-013-1451-5
143. G.Q. Phan, J.C. Yang, R.M. Sherry, P. Hwu, S.L. Topalian, D.J. Schwartzentruber, N.P. Restifo, L.R. Haworth, C.A. Seipp, L.J. Freezer, K.E. Morton, S.A. Mavroukakis, P.H. Duray, S.M. Steinberg, J.P. Allison, T.A. Davis, and S.A. Rosenberg Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proc. Natl. Acad. Sci. U. S. A. 100 2003 2003 8372 8377 10.1073/pnas.1533209100
144. B.C. Carthon, J.D. Wolchok, J. Yuan, A. Kamat, D.S. Ng Tang, J. Sun, G. Ku, P. Troncoso, C.J. Logothetis, J.P. Allison, and P. Sharma Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial Clin. Cancer Res. 16 2010 2010 2861 2871 10.1158/1078-0432.CCR-10-0569
145. Food and Drug Administration (FDA) Yervoy® (Ipilimumab) http://www.cancer.gov/cancertopics/druginfo/fda-ipilimumab 2011 (Accessed at March 2015)
146. European Medicines Agency (EMA) Yervoy® (ipilimumab) http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/human/002213/WC500109303.pdf 2011 (Accessed at May 2015)
147. R.V. Parry, J.M. Chemnitz, K.A. Frauwirth, A.R. Lanfranco, I. Braunstein, S.V. Kobayashi, P.S. Linsley, C.B. Thompson, and J.L. Riley CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms Mol. Cell. Biol. 25 2005 2005 9543 9553 10.1128/MCB.25.21.9543-9553.2005
148. B.A. Inman, T.J. Sebo, X. Frigola, H. Dong, E.J. Bergstralh, I. Frank, Y. Fradet, L. Lacombe, and E.D. Kwon PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression Cancer 109 2007 2007 1499 1505 10.1002/cncr.22588
149. R.S. Herbst, J.C. Soria, M. Kowanetz, G.D. Fine, O. Hamid, M.S. Gordon, J.A. Sosman, D.F. McDermott, J.D. Powderly, S.N. Gettinger, H.E. Kohrt, L. Horn, D.P. Lawrence, S. Rost, M. Leabman, Y. Xiao, A. Mokatrin, H. Koeppen, P.S. Hegde, I. Mellman, D.S. Chen, and F.S. Hodi Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 2014 563 567 10.1038/nature14011
150. Food and Drug Administration (FDA) Keytruda® (pembrolizumab) http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm412861.htm 2014 (Accessed at April 2015)
151. Food and Drug Administration (FDA) Opdivo®(nivolumab) http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm436566.htm 2015 (Accessed at May 2015)
152. S.N. Gettinger, L. Horn, L. Gandhi, D.R. Spigel, S.J. Antonia, N.A. Rizvi, J.D. Powderly, R.S. Heist, R.D. Carvajal, D.M. Jackman, L.V. Sequist, D.C. Smith, P. Leming, D.P. Carbone, M.C. Pinder-Schenck, S.L. Topalian, F.S. Hodi, J.A. Sosman, M. Sznol, D.F. McDermott, D.M. Pardoll, V. Sankar, C.M. Ahlers, M. Salvati, J.M. Wigginton, M.D. Hellmann, G.D. Kollia, A.K. Gupta, and J.R. Brahmer Overall survival and long-term safety of nivolumab (Anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer J. Clin. Oncol. 2015 2015 10.1200/JCO.2014.58.3708
153. J.H. Wang, and E.L. Reinherz Structural basis of T cell recognition of peptides bound to MHC molecules Mol. Immunol. 38 2002 2002 1039 1049
154. M. Kuroki, and N. Shirasu Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens Anticancer Res. 34 2014 2014 4481 4488
155. S.A. Rosenberg Progress in human tumour immunology and immunotherapy Nature 411 2001 2001 380 384 10.1038/35077246
156. J. Thibodeau, M.C. Bourgeois-Daigneault, and R. Lapointe Targeting the MHC class II antigen presentation pathway in cancer immunotherapy Oncoimmunology 1 2012 2012 908 916 10.4161/onci.21205
157. T.K. Hoffmann, K. Nakano, E.M. Elder, G. Dworacki, S.D. Finkelstein, E. Appella, T.L. Whiteside, and A.B. DeLeo Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants J. Immunol. 165 2000 2000 5938 5944
158. X. Zhu, H.J. Belmont, S. Price-Schiavi, B. Liu, H.I. Lee, M. Fernandez, R.L. Wong, J. Builes, P.R. Rhode, and H.C. Wong Visualization of p53(264-272)/HLA-A∗0201 complexes naturally presented on tumor cell surface by a multimeric soluble single-chain T cell receptor J. Immunol. 176 2006 2006 3223 3232
159. H. Wong, J. Wen, L. You, W. Xu, A. Edwards, and P. Rhode Intravenous administration of a novel IL-2 fusion protein, ALT-801, inhibits bladder cancer in mouse models J. Immunol. 188 2012 2012 46.35
160. U.H. Weidle, G. Georges, and G. Tiefenthaler TCR-MHC/peptide interaction: prospects for new anti-tumoral agents Cancer Genomics Proteomics 11 2014 2014 267 277
161. J. Wen, X. Zhu, B. Liu, L. You, L. Kong, H.I. Lee, K.P. Han, J.L. Wong, P.R. Rhode, and H.C. Wong Targeting activity of a TCR/IL-2 fusion protein against established tumors Cancer Immunol. Immunother. 57 2008 1781-1794 2008 10.1007/s00262-008-0504-7
162. H.J. Belmont, S. Price-Schiavi, B. Liu, K.F. Card, H.I. Lee, K.P. Han, J. Wen, S. Tang, X. Zhu, J. Merrill, P.A. Chavillaz, J.L. Wong, P.R. Rhode, and H.C. Wong Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein Clin. Immunol. 121 2006 2006 29 39 10.1016/j.clim.2006.05.005
163. M.N. Fishman, J.A. Thompson, G.K. Pennock, R. Gonzalez, L.M. Diez, A.I. Daud, J.S. Weber, B.Y. Huang, S. Tang, P.R. Rhode, and H.C. Wong Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A∗0201 complex, in patients with advanced malignancies Clin. Cancer Res. 17 2011 2011 7765 7775 10.1158/1078-0432.CCR-11-1817
164. G.A. Pietersz, D.S. Pouniotis, and V. Apostolopoulos Design of peptide-based vaccines for cancer Curr. Med. Chem. 13 2006 2006 1591 1607
165. V. Ramakrishna, J.F. Treml, L. Vitale, J.E. Connolly, T. O'Neill, P.A. Smith, C.L. Jones, L.Z. He, J. Goldstein, P.K. Wallace, T. Keler, and M.J. Endres Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules J. Immunol. 172 2004 2004 2845 2852
166. R.K. Iles, R. Persad, M. Trivedi, K.B. Sharma, A. Dickinson, P. Smith, and T. Chard Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer Br. J. Urol. 77 1996 1996 61 69
167. M.A. Morse, R. Chapman, J. Powderly, K. Blackwell, T. Keler, J. Green, R. Riggs, L.Z. He, V. Ramakrishna, L. Vitale, B. Zhao, S.A. Butler, A. Hobeika, T. Osada, T. Davis, T. Clay, and H.K. Lyerly Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients Clin. Cancer Res. 17 2011 2011 4844 4853 10.1158/1078-0432.CCR-11-0891
168. R.K. Iles Ectopic hCGbeta expression by epithelial cancer: malignant behaviour, metastasis and inhibition of tumor cell apoptosis Mol. Cell. Endocrinol. 260-262 2007 2007 264 270 10.1016/j.mce.2006.02.019
169. S.A. Butler, M.S. Ikram, S. Mathieu, and R.K. Iles The increase in bladder carcinoma cell population induced by the free beta subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation Br. J. Cancer 82 2000 2000 1553 1556 10.1054/bjoc.2000.1177
170. L.Z. He, V. Ramakrishna, J.E. Connolly, X.T. Wang, P.A. Smith, C.L. Jones, M. Valkova-Valchanova, A. Arunakumari, J.F. Treml, J. Goldstein, P.K. Wallace, T. Keler, and M.J. Endres A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta Clin. Cancer Res. 10 2004 1920-1927 2004
171. S. Gnjatic, H. Nishikawa, A.A. Jungbluth, A.O. Gure, G. Ritter, E. Jager, A. Knuth, Y.T. Chen, and L.J. Old NY-ESO-1: review of an immunogenic tumor antigen Adv. Cancer Res. 95 2006 2006 1 30 10.1016/S0065-230X(06)95001-5
172. Y. Fradet, V. Picard, A. Bergeron, and H. LaRue Cancer-testis antigen expression in bladder cancer Prog. Urol. 16 2006 2006 421 428
173. L. Dyrskjot, K. Zieger, T. Kissow Lildal, T. Reinert, O. Gruselle, T. Coche, M. Borre, and T.F. Orntoft Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma Br. J. Cancer 107 2012 2012 116 122 10.1038/bjc.2012.215
174. P. Sharma, S. Gnjatic, A.A. Jungbluth, B. Williamson, H. Herr, E. Stockert, G. Dalbagni, S.M. Donat, V.E. Reuter, D. Santiago, Y.T. Chen, D.F. Bajorin, and L.J. Old Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1T-cell epitope in a patient with bladder cancer Cancer Immun. 3 2003 2003 19
175. P. Sharma, Y. Shen, S. Wen, D.F. Bajorin, V.E. Reuter, L.J. Old, and A.A. Jungbluth Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma Clin. Cancer Res. 12 2006 2006 5442 5447 10.1158/1078-0432.CCR-06-0527
176. T. Nicholaou, L. Ebert, I.D. Davis, N. Robson, O. Klein, E. Maraskovsky, W. Chen, and J. Cebon Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1 Immunol. Cell Biol. 84 2006 2006 303 317 10.1111/j.1440-1711.2006.01446.x
177. P. Sharma, D.F. Bajorin, A.A. Jungbluth, H. Herr, L.J. Old, and S. Gnjatic Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF J. Immunother. 31 2008 2008 849 857 10.1097/CJI.0b013e3181891574
178. L. Bonifaz, D. Bonnyay, K. Mahnke, M. Rivera, M.C. Nussenzweig, and R.M. Steinman Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8 + T cell tolerance J. Exp. Med. 196 2002 2002 1627 1638
179. E. Fernandes, J.A. Ferreira, P. Andreia, L. Luis, S. Barroso, B. Sarmento, and L.L. Santos New trends in guided nanotherapies for digestive cancers: a systematic review J. Control. Release 209 2015 2015 288 307 10.1016/j.jconrel.2015.05.003
180. A.P. Mitra, and S.P. Lerner Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond Urol. Clin. N. Am. 42 2015 2015 201 215 10.1016/j.ucl.2015.01.003
181. L. Lima, D. Oliveira, J.A. Ferreira, A. Tavares, R. Cruz, R. Medeiros, and L. Santos The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guerin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population BJU Int 2014 2014 10.1111/bju.12844
182. L. Lima, P.F. Severino, M. Silva, A. Miranda, A. Tavares, S. Pereira, E. Fernandes, R. Cruz, T. Amaro, C.A. Reis, F. Dall'Olio, F. Amado, P.A. Videira, L. Santos, and J.A. Ferreira Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy Br. J. Cancer 109 2013 2013 2106 2114 10.1038/bjc.2013.571
183. L. Lima, J.A. Ferreira, A. Tavares, D. Oliveira, A. Morais, P.A. Videira, R. Medeiros, and L. Santos FASL polymorphism is associated with response to bacillus Calmette-Guerin immunotherapy in bladder cancer Urol. Oncol. 32 2014 2014 10.1016/j.urolonc.2013.05.009 (44 e41-47)
184. L. Lima, D. Oliveira, A. Tavares, T. Amaro, R. Cruz, M.J. Oliveira, J.A. Ferreira, and L. Santos The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure Urol. Oncol. 32 2014 2014 449 457 10.1016/j.urolonc.2013.10.012
185. J. Santos, E. Fernandes, J.A. Ferreira, L. Lima, A. Tavares, A. Peixoto, B. Parreira, J.M. Correia da Costa, P.J. Brindley, C. Lopes, and L.L. Santos P53 and cancer-associated sialylated glycans are surrogate markers of cancerization of the bladder associated with Schistosoma haematobium infection PLoS Negl. Trop. Dis. 8 2014 2014 e3329 10.1371/journal.pntd.0003329
186. C. Bernardo, C. Costa, T. Amaro, M. Goncalves, P. Lopes, R. Freitas, F. Gartner, F. Amado, J.A. Ferreira, and L. Santos Patient-derived sialyl-Tn-positive invasive bladder cancer xenografts in nude mice: an exploratory model study Anticancer Res. 34 2014 2014 735 744
187. J.A. Ferreira, P.A. Videira, L. Lima, S. Pereira, M. Silva, M. Carrascal, P.F. Severino, E. Fernandes, A. Almeida, C. Costa, R. Vitorino, T. Amaro, M.J. Oliveira, C.A. Reis, F. Dall'Olio, F. Amado, and L.L. Santos Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours Mol. Oncol. 7 2013 2013 719 731
188. M.A. Carrascal, P.F. Severino, M. Guadalupe Cabral, M. Silva, J.A. Ferreira, F. Calais, H. Quinto, C. Pen, D. Ligeiro, L.L. Santos, F. Dall'Olio, and P.A. Videira Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells Mol. Oncol. 8 2014 2014 753 765 10.1016/j.molonc.2014.02.008